Overview
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Description
The purpose of this study is to collect medical informations and samples (blood, bone marrow and/or lymph node) from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms (BCL2 mutations, over-expression of other members of the BCL2 protein family and energy metabolism changes).
Eligibility
Inclusion Criteria:
- Age greater than or equal to 18 years old;
- chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
- refractory and/or relapsed disease during or after venetoclax treatment;
- tumor samples available.
- Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome.
- Patients must be able to express their opposition to be enrolled in this study, if need be.
- Patients must be affiliated at the French Social Security system
Exclusion Criteria:
Patients of their legal guardians refusing to participate
-